Research shows, A simple blood test can accurately differentiate between benign and malignant Lesions


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Research shows, A simple blood test can accurately differentiate between benign and malignant Lesions
The investigators could also establish precise organ affected by the tumour with more than 90% accuracy

A large, landmark study published in the American Cancer Society's prestigious journal 'Cancer Cytopathology' shows that a simple non-invasive blood test (liquid biopsy) can accurately differentiate between non-cancerous tumours versus cancerous growths.

These findings were based on a multi-institutional, international collaborative study sponsored by Datar Cancer Genetics where the investigators evaluated blood samples from more than 30,000 participants, which included ~9,000 known cases and ~6,000 suspected cases of cancers, 700 individuals with non-cancerous tumors and 14,000 healthy individuals. The study encompassed 27 types of solid organ cancers including brain tumors.

The investigators evaluated the presence of circulating, tiny clusters of tumours, highly prevalent in the blood of cancer patients and undetectable in individuals without cancer. The investigators could also establish precise organ affected by the tumour with more than 90% accuracy.

Significantly, the test will greatly help individuals reporting with suspicious growths in various organs such as breast, lung, prostate, colon, brain. It is noteworthy that a large proportion of individuals who undergo biopsy on suspicion of malignancy are detected with benign tumours who could be spared risky invasive and resource intensive biopsies. Also, the blood test can help in the diagnosis of cases where invasive biopsies are unviable due to various reasons such as location of the tumour close to a vital organ or blood vessel or reluctance of patients besides co-morbidities.

The technology and the test are developed by Datar Cancer Genetics. The test is expected to be commercially available shortly. These findings are bound to have a profound impact on cancer diagnosis.

Commenting upon the results, Dr Nicholas Plowman, MD, Medical Oncologist at Department of Clinical Oncology, St Bartholomew's Hospital, London, United Kingdom, and one of the authors of the paper said that 'This study is the largest of its kind and shows the meaningful potential of liquid biopsies, which so far have been grossly under-rated, at least partly as the previous capture methods were inferior. Harvesting tumour clusters from peripheral blood is akin to a non-invasive micro-biopsy of the tumour. Evaluation of these clusters can facilitate diagnostic triaging as well as guidance in suspected cancer cases. The test is not only patient friendly, but it can also significantly reduce the burden on the already overburdened cancer diagnosis infrastructure.'

Tags : #DatarCancerGenetics #AmericanCancerSociety #LiquidBiopsies #Non-invasiveMicro-Biopsy #LatestPharmaNews9thNov

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026